We are live on ! Find out more
BIOL

Biolase, Inc.
BIOL

Delisted

BIOL was delisted on the 18th of June, 2024.

Back to rankings

22 hedge funds and large institutions have $1.49M invested in Biolase, Inc. in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

232% more capital invested

Capital invested by funds: $448K → $1.49M (+$1.04M)

167% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 3

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

16% more funds holding

Funds holding: 19 → 22 (+3)

Holders
22
Holders Change
+3
Holders Change %
+15.79%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PCM
Perkins Capital Management
Minnesota
+$1.3M
2
AIC
AWM Investment Company
New York
+$944K
3
Renaissance Technologies
Renaissance Technologies
New York
+$46.6K
4
VF
Virtu Financial
New York
+$17.4K
5
ZF
Zhang Financial
Michigan
+$10.2K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$81.3K
2
HF
HRT Financial
New York
-$19K
3
TSS
Two Sigma Securities
New York
-$7.24K
4
BlackRock
BlackRock
New York
-$2.92K
5
Morgan Stanley
Morgan Stanley
New York
-$973
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
1
Perkins Capital Management
Minnesota
$766K +$1.3M +26,773 +5,795%
AIC
2
AWM Investment Company
New York
$545K +$944K +19,386 New
Renaissance Technologies
3
Renaissance Technologies
New York
$39K +$46.6K +957 +222%
BlackRock
4
BlackRock
New York
$33.3K -$2.92K -60 -5%
Vanguard Group
5
Vanguard Group
Pennsylvania
$26.5K -$81.3K -1,671 -64%
VF
6
Virtu Financial
New York
$17K +$17.4K +358 +150%
Prudential Financial
7
Prudential Financial
New Jersey
$16.5K +$8.08K +166 +39%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$15.4K – – –
Northern Trust
9
Northern Trust
Illinois
$8.43K +$9.15K +188 +168%
ZF
10
Zhang Financial
Michigan
$5.88K +$10.2K +209 New
State Street
11
State Street
Massachusetts
$4.9K – – –
BBA
12
Baader Bank Aktiengesellschaft
Germany
$2.24K +$4.96K +102 New
TRCT
13
Tower Research Capital (TRC)
New York
$2K +$973 +20 +38%
UBS Group
14
UBS Group
Switzerland
$1.01K +$925 +19 +112%
OCM
15
Orion Capital Management
California
$562 – – –
Citigroup
16
Citigroup
New York
$561 +$973 +20 New
IA
17
IFP Advisors
Florida
$373 – – –
Morgan Stanley
18
Morgan Stanley
New York
$363 -$973 -20 -61%
Osaic Holdings
19
Osaic Holdings
Arizona
$66 – – –
Wells Fargo
20
Wells Fargo
California
$47 +$97 +2 New
Commonwealth Equity Services
21
Commonwealth Equity Services
Massachusetts
$7 +$7.3K +150 +140%
Bank of America
22
Bank of America
North Carolina
$4 – – –
FWM
23
Focused Wealth Management
New York
$2 – – –
HNB
24
Huntington National Bank
Ohio
$1 – – –
HF
25
HRT Financial
New York
– -$19K -303 Closed
1
2

BIOL Hedge Fund Activity: Q1 2023 in Review

22 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q1 2023, worth a combined $1.49M — up 232% from $448K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new BIOL positions and 2 closed out — a net gain of 3 holders — while 8 added to existing stakes and 3 trimmed.

The largest buyer was Perkins Capital Management, adding an estimated $1.3M. The largest seller was Vanguard Group, cutting an estimated $81.3K.

  • 22 institutional investors held Biolase, Inc. (BIOL) as of Q1 2023, up from 19 in Q4 2022.
  • Funds reported $1.49M of Biolase, Inc. stock for Q1 2023, up 232% quarter-over-quarter.
  • 5 funds opened new Biolase, Inc. positions in Q1 2023 and 2 closed out, a net change of +3 holders.
  • The largest Biolase, Inc. buyer in Q1 2023 was Perkins Capital Management, an estimated $1.3M added.
  • The largest Biolase, Inc. seller in Q1 2023 was Vanguard Group, an estimated $81.3K sold.

Based on aggregated 13F filings for Q1 2023.